Christine Regan Lindenboom | Alnylam Pharmaceuticals, Inc. |
John M. Maraganore, Ph.D. | Alnylam Pharmaceuticals, Inc. |
Akshay K. Vaishnaw | Alnylam Pharmaceuticals, Inc. |
Manmeet S. Soni | Alnylam Pharmaceuticals, Inc. |
Yvonne L. Greenstreet | Alnylam Pharmaceuticals, Inc. |
Terence Flynn | Goldman Sachs & Co. LLC |
Vincent Chen | Sanford C. Bernstein & Co. LLC |
Ted A. Tenthoff | Piper Jaffray & Co. |
Mike G. King | JMP Securities LLC |
Maury Raycroft | Jefferies LLC |
Gena Wang | Barclays Capital, Inc. |
Benjamin Burnett | Leerink Partners LLC |
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals Conference Call to discuss The Third Quarter 2017 Financial Results. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company's request. I would now turn the call over to the company.